TUMOR NECROSIS FACTOR-α AND MONOCYTE CHEMOATTRACTANT PROTEIN-1 AS BIOMARKERS IN CHRONIC MYELOID LEUKEMIA
Abstract
Chronic myeloproliferative neoplasms (MPN) are specific clonal hematopoietic
stem-cell disorders that continuously and without interruption activate the physiologic
signal-transduction pathways necessary for normal and adequate hematopoiesis. A
marked proinflammatory milieu in chronic myeloid leukemia (CML) is led by many
interleukins. This study aimed to evaluate differences in plasma levels of tumor necrosis
factor- α (TNF-α) and monocyte chemoattractant protein (MCP-1) between chronic-phase
CML patients and healthy individuals as controls.
The study included 50 consecutive patients diagnosed with CML in the chronic
phase and under the standard tyrosine kinase inhibitor (TKI) treatment, as well as 20
healthy controls. Blood concentrations of tumor necrosis factor-α (TNF-α) and monocyte
Chemoattractant protein-1 (MCP-1) were measured by the enzyme-linked immunosorbent
assay method. The levels of MCP-1 were higher in patients than in controls (334.37 vs.
172.18 pg/ml, p = 0.006), while no difference was determined for TNF-α.
There is great importance of MCP-1 and IL-6 as novel, strong, and predictive
plasma biomarkers for treatment-free remission in CML. Additional and future research in
this field will be of special and great importance in understanding the pathophysiology and
treatment of myeloproliferative diseases.
References
Anand M, Chodda SK, Parikh PM, Nadkarni JS. Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myeloid leukemia in different stages, and their role in prognosis. Hematol Oncol 1998;16(4):143–54. [CrossRef] [PubMed]
Branford S. Why is it critical to achieve a deep molecular response in chronic myeloid leukemia? Haematologica 2020;105(12):2730–7. [CrossRef] [PubMed]
Camacho V, Kuznetsova V, Welner RS. Inflammatory cytokines shape an altered immune response during myeloid malignancies. Front Immunol 2021;12:772408. [CrossRef] [PubMed]
Cashman JD, Eaves CJ, Sarris AH, Eaves AC (1998) MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood 1998;92(7):2338-44. [CrossRef] [PubMed]
Copland M. Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity. Br J Haematol 2022;199(5):665–78. [CrossRef] [PubMed]
Fisher DAC, Fowles JS, Zhou A, Oh ST. Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms. Front Immunol 2021;12 683401. [CrossRef] [PubMed]
Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, et al. Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood 2013;122(19):3335–9. [CrossRef] [PubMed]
Hoermann G, Greiner G, Valent P. Cytokine regulation of microenvironmental cells in myeloproliferative neoplasms. Mediators Inflamm. 2015;2015:869242. [CrossRef] [PubMed]
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022;36(7):1703–19. [CrossRef] [PubMed]
Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK–STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov 2015;5(3):316–31. [CrossRef] [PubMed]
Masselli E, Pozzi G, Gobbi G, Merighi S, Gessi S, Vitale M, et al. Cytokine profiling in myeloproliferative neoplasms: Overview on phenotype correlation, outcome prediction, and role of genetic variants. Cells 2020;9(9):2136. [CrossRef] [PubMed]
Mulholland BS, Forwood MR, Morrison NA. Monocyte chemoattractant protein-1 (MCP-1/CCL2) drives activation of bone remodelling and skeletal metastasis. Curr Osteoporos Rep 2019;17(6):538–47. [CrossRef] [PubMed]
Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ, et al. TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia 2016;30(6):1263–72. [CrossRef] [PubMed]
Nishida A, Andoh A. The role of inflammation in cancer: Mechanisms of tumor initiation, progression, and metastasis. Cells 2025;14(7):488. [CrossRef] [PubMed]
Pavlovsky C, Cordoba BV, Sanchez MB, Moiraghi B, Varela A, Custidiano R, et al. Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal. J Hematol Oncol 2023;16(1):43. [CrossRef] [PubMed]
Wang Y, Zuo X. Cytokines frequently implicated in myeloproliferative neoplasms. Cytokine X 2019;1(1):100005. [CrossRef] [PubMed]
Wolf AM, Wolf D, Rumpold H, Ludwiczek S, Enrich B, Gastl G, et al. The kinase inhibitor imatinib mesylate inhibits TNF-α production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci U S A 2005;102(38):13622–7. [CrossRef] [PubMed]
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews Cancer 2009;9(11):798–809. [CrossRef] [PubMed]
